Futibatinib

Published

dm+d

Unassigned

New Medicines

Advanced solid tumours with FGFR1-4 genetic aberration, including cholangiocarcinoma

Information

New molecular entity
Taiho Oncology
Taiho Oncology

Development and Regulatory status

Phase II Clinical Trials
Phase II Clinical Trials
Phase III Clinical Trials
Yes

Category

Irreversible covalently-binding FGFR inhibitor of fibroblast growth factor receptors 1, 2, 3 and 4 (reduces tumour cell proliferation)
Cholangiocarcinoma (CCA), also known as bile duct cancer, is not common. About 8,000 people in the U.S. are diagnosed with CCA each year.4 This includes both intrahepatic (inside the liver) and extrahepatic (outside the liver) cancers. CCA can occur at younger ages, but it is seen mainly in older people. Five year survival is 9% [1].
Advanced solid tumours with FGFR1-4 genetic aberration, including cholangiocarcinoma
Oral